Genrix Bio: GR2303 injection has obtained the drug clinical trial approval notice
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Genrix Bio announced that the company has recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for the company's research product GR2303 injection has been approved, allowing the clinical trial for inflammatory bowel disease indications to proceed. As of the announcement date, there are no other drugs targeting the same indication as GR2303 injection approved for marketing in China
According to the Zhitong Finance APP, Genrix Bio (688443.SH) announced that it has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for the company's investigational product GR2303 injection has been approved, allowing the clinical trial for the indication of inflammatory bowel disease to proceed.
As of the announcement date, there are no drugs targeting the same indication as GR2303 injection approved for marketing in China